Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Epidemiological characteristics and adverse events of patients with psoriatic arthritis undergoing treatment with biological therapies in Galicia
Carlos García Porrúa; Francisco José Maceiras Pan; José Antonio Mosquera Martínez; Loreto Carmona; Blanca Correa Rey; Luis Fernández Domínguez; María Noelia Álvarez Rivas; José Antonio Pinto Tasende;
Reumatol Clin. 2021;17:150-4
Secukinumab as biological treatment for psoriatic arthritis in real clinical practice
José A. Pinto Tasende; Francisco J. Maceiras Pan; José A. Mosquera Martínez; Luis Fernández Dominguez; Blanca Correa Rey; Carlos García Porrúa;
Reumatol Clin. 2021;17:203-6
One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry
Clementina López-Medina; Lucía Otero-Varela; Fernando Sánchez-Alonso; Vega Jovaní; Lorena Expósito-Pérez; Sheila Melchor-Díaz; Yanira Pérez-Vera; Paula Pretel-Ruiz; Javier Manero; Antonio Mera-Varela; Lourdes Mateo; Dolores Ruiz-Montesino; José Andrés Lorenzo-Martín; Teresa Pedraz-Penalva; Isabel Castrejón;
Reumatol Clin. 2025;21: